NCT03641586View on ClinicalTrials.gov

The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor

PHASE1CompletedINTERVENTIONAL

Enrollment

42

Participants

Timeline

Start Date

October 12, 2015

Primary Completion Date

December 6, 2016

Study Completion Date

March 7, 2019

Conditions

Solid Tumors

Interventions

DRUG

BGB-283

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

Sponsors

Lead Sponsor

All Listed Sponsors

lead

BeiGene

INDUSTRY